Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CMPX

Compass Therapeutics Inc

Nov 07 • 04:00PM ET

4.23

+0.23 5.75 %

Healthcare • Biotechnology • USA • NASD

Peers: FATE ADAP KPTI PGEN ARGX TGTX BPMC MRNA VRTX

| Held by: VTI IWM VXF XBI IWO VTWO IWN IWC VFMO LABU

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.46	Insider Own	28.34%	Shs Outstand	177.57M	Perf Week	13.10%
Market Cap	752.36M	Forward P/E	-	EPS next Y	-0.43	Insider Trans	0.02%	Shs Float	127.47M	Perf Month	3.93%
Enterprise Value	542.33M	PEG	-	EPS next Q	-0.10	Inst Own	49.35%	Short Float	12.05%	Perf Quarter	26.65%
Income	-65.80M	P/S	-	EPS this Y	-24.93%	Inst Trans	2.76%	Short Ratio	9.56	Perf Half Y	132.42%
Sales	0.00M	P/B	3.58	EPS next Y	5.44%	ROA	-34.60%	Short Interest	15.36M	Perf YTD	191.72%
Book/sh	1.18	P/C	3.42	EPS next 5Y	0.26%	ROE	-37.82%	52W High	4.86 -12.96%	Perf Year	141.71%
Cash/sh	1.24	P/FCF	-	EPS past 3/5Y	23.88% -104.70%	ROIC	-30.07%	52W Low	1.27 233.07%	Perf 3Y	11.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.23% 7.87%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-28.79%	Oper. Margin	-	ATR (14)	0.29	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	17.82	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	59.60	Recom	1.09
Dividend Gr. 3/5Y	- -	Current Ratio	17.82	EPS Q/Q	-10.89%	SMA20	3.96%	Beta	1.28	Target Price	12.73
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	12.01%	Rel Volume	1.53	Prev Close	4.00
Employees	35	LT Debt/Eq	0.04	Earnings	Nov 05 BMO	SMA200	48.03%	Avg Volume	1.61M	Price	4.23
IPO	Apr 05, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	42.53% -	Trades		Volume	2,455,658	Change	5.75%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-01-25	Resumed	Raymond James	Outperform	$9
Apr-02-25	Upgrade	Leerink Partners	Market Perform → Outperform	$6
Feb-24-25	Initiated	Guggenheim	Buy	$12
Feb-19-25	Initiated	Piper Sandler	Overweight	$12
Dec-23-24	Initiated	D. Boral Capital	Buy	$32
Nov-15-24	Downgrade	Leerink Partners	Outperform → Market Perform	$5 → $4
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy	$5
Jan-31-23	Initiated	Jefferies	Buy	$8
Jan-27-23	Initiated	Stifel	Buy	$9
May-23-22	Resumed	H.C. Wainwright	Buy	$12
Mar-15-22	Initiated	Ladenburg Thalmann	Buy	$7
Jan-19-22	Initiated	B. Riley Securities	Buy	$10
Dec-22-21	Initiated	Raymond James	Outperform	$5
Dec-20-21	Initiated	SVB Leerink	Outperform	$12
Dec-15-21	Initiated	Wedbush	Outperform	$8

Show Previous Ratings

Nov-05-25 07:30AM	Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-25 09:00AM	Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-03-25 08:00AM	Compass Therapeutics to Participate in Upcoming November Investor Events (GlobeNewswire)
Oct-30-25 11:29PM	Piper Sandler Remains Bullish on Compass Therapeutics (CMPX) (Insider Monkey)
Sep-11-25 03:31AM	Guggenheim Sees Compass (CMPX) Potential Driven by Biliary Tract Cancer Pipeline (Insider Monkey)
12:57AM	Loading…
Sep-02-25 12:57AM	Piper Sandler Reaffirms Optimism on Compass Therapeutics (CMPX) Amid Trial Update (Insider Monkey)
Aug-26-25 08:00AM	Compass Therapeutics to Participate in Upcoming September Investor Events (GlobeNewswire)
Aug-20-25 12:22AM	Compass Therapeutics (CMPX) Rated 'Outperform' amid Clinical Pipeline Development (Insider Monkey)
Aug-12-25 10:28PM	Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering (GlobeNewswire) -5.09%
04:01PM	Compass Therapeutics Announces Proposed Public Offering (GlobeNewswire)
03:03AM	Compass Therapeutics Inc (CMPX) Q2 2025 Earnings Call Highlights: Promising Clinical Advances ... (GuruFocus.com)
Aug-11-25 07:00AM	Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire) +23.70%
Aug-08-25 04:01PM	Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025 (GlobeNewswire)
Jul-25-25 12:09PM	Stifel Keeps Buy Rating on Compass Therapeutics (CMPX) (Insider Monkey)
Jul-22-25 11:03AM	Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline (Insider Monkey)
08:00AM	Loading…
May-28-25 08:00AM	Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-08-25 08:00AM	Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
May-06-25 08:00AM	Compass Therapeutics to Participate in Upcoming May Investor Events (GlobeNewswire) -9.14%
Apr-28-25 08:00AM	Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-21-25 08:00AM	Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer (GlobeNewswire)
Apr-02-25 04:05PM	Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum (GlobeNewswire) -24.55% -5.03%
Apr-01-25 07:00AM	Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer (GlobeNewswire) +17.89%
Mar-31-25 04:05PM	Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer (GlobeNewswire)
Mar-27-25 10:20AM	Is Compass Therapeutics (CMPX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-02-25 10:22AM	Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-27-25 08:00AM	Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-29-25 08:00AM	Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-08-25 08:00AM	Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate (GlobeNewswire) +30.07%
Dec-10-24 08:00AM	Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer (GlobeNewswire) +7.88%
Dec-02-24 08:00AM	Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
08:30AM	Loading…
Nov-13-24 08:30AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire) -5.59%
Nov-12-24 08:00AM	Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire) -5.79%
Nov-08-24 10:05AM	Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Oct-04-24 10:31AM	Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-03-24 08:00AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-12-24 08:00AM	Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-24 08:00AM	Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference (GlobeNewswire) -6.52%
Aug-06-24 08:00AM	Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer (GlobeNewswire)
Jul-10-24 12:00PM	Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's Why (Zacks) +9.94%
May-30-24 08:00AM	Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -7.48%
May-28-24 04:10PM	Compass Therapeutics Announces CEO Transition (GlobeNewswire)
May-23-24 05:05PM	Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 (GlobeNewswire)
May-14-24 08:00AM	Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
May-13-24 02:53PM	CMPX Stock Earnings: Compass Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-25-24 08:00AM	Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated (GlobeNewswire)
Apr-16-24 08:00AM	Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors (GlobeNewswire)
Apr-12-24 08:00AM	Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference (GlobeNewswire)
Apr-10-24 08:00AM	Compass Therapeutics to Participate in the Stifel Targeted Oncology Days (GlobeNewswire)
Apr-09-24 12:00PM	Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-21-24 10:54PM	CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +5.66%
09:00AM	Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-29-24 08:00AM	Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-28-24 08:00AM	Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial (GlobeNewswire)
Feb-08-24 12:00PM	Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know (Zacks) +8.21%
Jan-05-24 08:00AM	Compass Therapeutics Provides Corporate Update (GlobeNewswire) +5.16%
Nov-09-23 08:17AM	Compass Therapeutics Inc (CMPX) Reports Q3 2023 Financial Results and Corporate Developments (GuruFocus.com) -6.40%
07:30AM	Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-23 08:00AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-30-23 08:00AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-03-23 08:00AM	Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-22-23 04:05PM	Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes (GlobeNewswire)
Jun-01-23 10:06AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
May-04-23 08:30AM	Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-26-23 08:30AM	Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Apr-19-23 08:30AM	Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days (GlobeNewswire) -5.00%
Mar-28-23 08:30AM	Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium (GlobeNewswire)
Mar-15-23 08:30AM	Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-16-23 07:28AM	Daily Vickers Top Buyers & Sellers for 02/16/2023 (Argus Research)
Feb-02-23 08:30AM	Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-25-23 06:39AM	Daily Vickers Top Buyers & Sellers for 01/25/2023 (Argus Research)
Jan-19-23 05:00PM	Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023 (GlobeNewswire) -10.93%
Jan-06-23 08:30AM	Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer (GlobeNewswire)
Dec-15-22 08:30AM	Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21 (GlobeNewswire)
Dec-01-22 08:30AM	Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab) (GlobeNewswire) +11.92%
Nov-22-22 08:00AM	Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-09-22 09:00AM	Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-08-22 08:00AM	Compass Therapeutics to Present at Upcoming Investment Conferences (GlobeNewswire) +10.10%
Nov-02-22 09:06AM	Compass Therapeutics Announces $80 Million Private Placement (GlobeNewswire) +10.53%
Oct-11-22 08:00AM	Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA® (pembrolizumab) (GlobeNewswire) +8.80%
Sep-09-22 08:00AM	Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-02-22 08:00AM	Compass Therapeutics to Present at the 13th Annual Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Aug-01-22 08:00AM	Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-18-22 07:05AM	Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position (GlobeNewswire)
May-31-22 08:00AM	Compass Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-22 08:00AM	Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference (GlobeNewswire) +6.56%
May-20-22 06:28AM	Trade Alert: The Co-Founder Of Compass Therapeutics, Inc. (NASDAQ:CMPX), Thomas Schuetz, Has Just Spent US$50k Buying A Few More Shares (Simply Wall St.) +6.65%
May-16-22 08:00AM	Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy (GlobeNewswire) +5.12%
May-09-22 01:59PM	Here's What Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Shareholder Ownership Structure Looks Like (Simply Wall St.)
08:00AM	Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-05-22 08:00AM	Compass Therapeutics to Present at the Bank of America Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 11:20 a.m. PT (GlobeNewswire)
May-04-22 07:00AM	Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers (GlobeNewswire)
May-03-22 04:01PM	Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009 (GlobeNewswire)
Apr-26-22 08:00AM	Compass Therapeutics Announces Appointment of Two New Directors to its Board (GlobeNewswire)
Apr-08-22 01:01PM	Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting (GlobeNewswire) -6.71%
Mar-30-22 08:00AM	Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans (GlobeNewswire) +5.56%
Mar-21-22 08:00AM	Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +6.15%
Feb-07-22 05:38PM	Monashee Investment Management LLC Buys Vanguard Total Stock Market ETF, Hyperfine Inc, Agree ... (GuruFocus.com) +9.39%
Jan-28-22 05:38PM	New Capital Management LP Buys Compass Therapeutics Inc, Sells Cambria Shareholder Yield ETF (GuruFocus.com) -6.42%
Jan-20-22 08:30AM	Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A) (GlobeNewswire) -5.30%

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schuetz Thomas J.	CHIEF EXECUTIVE OFFICER	May 27 '25	Buy	2.11	10,000	21,100	6,480,825	May 27 03:24 PM
GORDON CARL L	Director	Apr 09 '25	Sale	1.59	3,571,428	5,678,571	0	Apr 11 07:37 PM
ORBIMED ADVISORS LLC	Director	Apr 09 '25	Sale	1.59	3,571,428	5,678,571	0	Apr 11 07:24 PM
OrbiMed Genesis Master Fund, L	Director	Apr 09 '25	Proposed Sale	1.59	3,571,428	5,678,571		Apr 09 06:58 PM
The Biotech Growth Trust PLC	Director	Apr 09 '25	Proposed Sale	1.59	3,571,428	5,678,571		Apr 09 06:51 PM
Anderman Jonathan	Gen Counsel & Corporate Sec	Apr 07 '25	Buy	1.54	20,000	30,800	21,000	Apr 08 09:30 AM
Lerner Neil	CHIEF ACCOUNTING OFFICER	Apr 07 '25	Buy	1.42	20,000	28,400	320,000	Apr 08 09:25 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CMPX

Compass Therapeutics Inc

Upgrade your FINVIZ experience